Microbio Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Hsien-Shou Kuo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.8yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	11.8yrs

Recent management updates

Recent updates

Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Jan 04

CEO

Hsien-Shou Kuo (82 yo)

1.8yrs

Tenure

Mr. Hsien-Shou Kuo serves as Chairman of the Board at Microbio Co., Ltd. since December 20, 2021 and serves as its General Manager since July 2022. He serves as Independent Director at TaiRx, Inc. He serve...

Board Members

Name	Position	Tenure	Compensation	Ownership
Hsien-Shou Kuo	Chairman & GM	2.3yrs	no data	no data
Pan-Chi Yang	Representative Director	3.8yrs	no data	no data
Cheng-Tsung Huang	Director	11.8yrs	no data	no data
Yuan-He Lai	Independent Director	20.8yrs	no data	no data
Kao-Chung Tsai	Independent Director	17.9yrs	no data	no data
Li-Chun Han	Independent Director	11.8yrs	no data	no data
Chi-Ming Liang	Independent Director	2.7yrs	no data	no data

11.8yrs

Average Tenure

71yo

Average Age

Experienced Board: 4128's board of directors are seasoned and experienced ( 11.8 years average tenure).

Microbio Management

Management criteria checks 1/4

Key information

Recent management updates

Microbio Co., Ltd., Annual General Meeting, May 30, 2024

Microbio Co., Ltd., Annual General Meeting, Apr 18, 2023

Microbio Co., Ltd. Establishes Sustainable Development Committee

Microbio Co., Ltd. Announces Executive Changes

Microbio Co., Ltd., Annual General Meeting, Apr 29, 2022

Microbio Co., Ltd., Annual General Meeting, May 28, 2021

Recent updates

Full year 2023 earnings released: NT$2.11 loss per share (vs NT$0.38 profit in FY 2022)

Microbio Co., Ltd., Annual General Meeting, May 30, 2024

New major risk - Revenue and earnings growth

Microbio Co.,Ltd. Submits 510(K) Application for Medical Device Mb107 Cream to the U.S. FDA

Second quarter 2023 earnings released: NT$0.88 loss per share (vs NT$1.00 loss in 2Q 2022)

Upcoming dividend of NT$0.04 per share at 0.1% yield

Full year 2022 earnings released: EPS: NT$0.41 (vs NT$0.099 in FY 2021)

Microbio Co., Ltd., Annual General Meeting, Apr 18, 2023

Microbio Co., Ltd. Establishes Sustainable Development Committee

Investor sentiment improved over the past week

Microbio Co., Ltd. Announces Executive Changes

Upcoming dividend of NT$0.04 per share

Microbio Co., Ltd. Announces Cash Dividend, Payment Date of Cash Dividend Distribution Will Suppose to Be on August 8Th, 2022

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$1.74 (vs NT$1.03 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Microbio Co., Ltd., Annual General Meeting, Apr 29, 2022

Third quarter 2021 earnings released: EPS NT$0.04 (vs NT$1.29 in 3Q 2020)

Second quarter 2021 earnings released: NT$1.98 loss per share (vs NT$5.32 profit in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.13 (vs NT$0.45 loss in 1Q 2020)

Microbio Co., Ltd. Announces Its Subsidiary, Microbioshanghai Receives Written Acceptance from CDE Under NMPA on the NDA Application for the DFU New Drug:On101

Microbio Co., Ltd., Annual General Meeting, May 28, 2021

Full year 2020 earnings released: EPS NT$1.68 (vs NT$0.57 loss in FY 2019)

Investor sentiment improved over the past week

New 90-day low: NT$53.90

New 90-day low: NT$58.20

Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Investor sentiment improved over the past week

New 90-day low: NT$66.80

Third quarter 2020 earnings released: EPS NT$1.41

New 90-day low: NT$72.30

CEO

Tenure

Board Members

Average Tenure

Average Age